Published on 1 Jun 2022 on Zacks via Yahoo Finance
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
The biotech sector has been in the spotlight in the past week, with regular pipeline and regulatory updates.
Recap of the Week’s Most Important Stories:
Updates From Bristol Myers: Bristol Myers Squibb BMY announced that the FDA has approved Opdivo (nivolumab) combinations for yet another indication. The regulatory body approved the drug (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. Concurrently, Opdivo in combination with Yervoy (ipilimumab) was also approved for the same indication by the FDA.